|
Feb 18
|
|
—
|
SHORT
|
Marty Makary
FDA Commissioner
|
Makary describes PBM "spread pricing" (where PBMs mark up drugs significantly) as a "money game" and "price gouging" that the administration "is not going to stand for." The FDA and administration are explicitly targeting the opaque profit margins of PBMs (like CVS Caremark, Optum, Express Scripts) to lower drug costs. This policy shift threatens their core profitability. SHORT the sector (CVS / CI / UNH) on regulatory headwinds. Lobbying efforts may dilute actual policy implementation. |
CNBC
FDA's Marty Makary: Everything should be over...
|